ResMed Astral 100 and Astral 150 Supercapacitor Recall: How Bemes Can Help
Understand the safety correction, plan your next steps, and get help from Bemes with your Astral 100 and Astral 150 recall and repair needs.
Certain ResMed Astral 100 and Astral 150 ventilators are affected by a supercapacitor safety recall. If your organization uses either model, reviewing the applicable notice and your equipment’s service history is an important step in planning service.
Do not stop using your ventilator unless directed by your treating clinician. Follow the applicable safety instructions and ensure backup ventilation equipment is available and ready for immediate use.
What is the supercapacitor issue?
The 2026 correction concerns an internal supercapacitor that may leak electrolyte and damage circuitry on the main printed circuit board assembly (PCBA). This can cause the ventilator to enter a fail-safe state and stop delivering ventilation.
The FDA classified the U.S. action as a Class I recall, its most serious classification. It involves correcting affected devices rather than a blanket instruction to remove every Astral from use. See the FDA safety notice and instructions.
Is your Astral 100 or Astral 150 affected?
The correction applies to a subset of devices and replacement circuit boards. Determining whether a unit is affected requires checking the main board currently installed—not simply the model name. A ventilator fitted with an unaffected main board is not impacted by this issue.
Confirm applicability with ResMed or your service provider using the device’s identification and service history.
Two notices. Different issues.
The earlier action, initiated in September 2023, concerned supercapacitor degradation that could shorten or prevent the Total Power Failure alarm. It covered devices manufactured between 2013 and 2019. A subsequent notice called for a software update through a service center.
The 2026 correction concerns electrolyte leakage that can damage the circuit board and interrupt ventilation. Completing an earlier service action should not be treated as confirmation that a unit is unaffected by the newer issue. Have the applicable notices and service records reviewed together.
References: Earlier FDA recall record and 2026 FDA recall record.
What should patients and equipment providers do?
Continue following the treating clinician’s instructions and applicable ResMed safety guidance. The FDA advises that affected users have backup ventilation equipment available and ready for immediate use while awaiting correction.
Replacement circuit boards are constrained, and ResMed is taking a prioritized, phased approach. Service timing and the appropriate corrective pathway must be confirmed for each unit.
BEMES SERVICE SUPPORT
We’re here to help.
Bemes can help with your Astral 100 and Astral 150 recall needs and unit repairs. Contact our team to discuss the notice you received, your equipment’s service needs, and the next steps for repair.
Have the following information available:
- Model and serial number
- A copy of the recall or correction notice
- Previous service and circuit-board replacement records
- Any displayed fault codes or reported equipment problems
Request Repair Call 866-490-1609
Email sales@bemeseast.com
Recall-specific work, replacement parts, pricing, and turnaround must be confirmed for your individual equipment. Routine repair work should not be assumed to complete a manufacturer’s recall correction.
Common questions
Does this affect both the Astral 100 and Astral 150?
Yes, certain units of both models are covered. Confirm the status of the installed main board with ResMed or your service provider.
Can every affected unit be corrected immediately?
Replacement circuit board supply is constrained. The corrective pathway and timing must be confirmed for your equipment.
How can Bemes help?
Our team can discuss your recall needs, review your equipment’s service requirements, and arrange the next steps for unit repairs. Call 866-490-1609 to get started.
Astral 150 shown in the manufacturer product photograph. Safety information reviewed September 17, 2026. Refer to the linked FDA notices and current ResMed instructions for complete guidance.